{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:12:43Z","timestamp":1762542763880},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"68","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,22]]},"DOI":"10.18632\/oncotarget.22938","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T04:03:15Z","timestamp":1512532995000},"page":"113287-113293","source":"Crossref","is-referenced-by-count":3,"title":["Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance"],"prefix":"10.18632","volume":"8","author":[{"given":"Xiyi","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZiJing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective","volume":"33","author":"Chan","year":"2015","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Le DT Durham, Smith, Wang, Bartlett, Aulakh, Lu, Kemberling, Wilt, Luber, Wong, Azad, Rucki, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017.","DOI":"10.1126\/science.aan6733"},{"key":"3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Speaker","year":"2016","journal-title":"Lancet Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-015-0222-5","article-title":"Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?","volume":"8","author":"Lin","year":"2015","journal-title":"J Hematol Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Bhatia","year":"2012","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14737140.2017.1311791","article-title":"Pembrolizumab for the treatment of non-small cell lung cancer","volume":"17","author":"Baas","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","volume":"315","author":"Dronca","year":"2016","journal-title":"JAMA"},{"key":"8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrclinonc.2014.221","article-title":"Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer","volume":"12","author":"Errico","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Zang","year":"2015","journal-title":"Trends Mol Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Kurzrock","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaoncol.2015.4685","article-title":"PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development","volume":"2","author":"Siu","year":"2016","journal-title":"JAMA Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Joshua","year":"2015","journal-title":"J Immunother Cancer"},{"key":"13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Zaheer","year":"2015","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/modpathol.2010.130","article-title":"Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma","volume":"23","author":"Chang","year":"2010","journal-title":"Mod Pathol"},{"key":"15","first-page":"505","article-title":"Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications","volume":"6","author":"Gaipl","year":"2015","journal-title":"Front Immunol"},{"key":"16","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1038\/cddis.2013.156","article-title":"Many faces of DAMPs in cancer therapy","volume":"4","author":"Krysko","year":"2013","journal-title":"Cell Death Dis"},{"key":"17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00262-013-1474-y","article-title":"Antitumor immune responses induced by ionizing irradiation and further immune stimulation","volume":"63","author":"Gaipl","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen","volume":"3","author":"Drake","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Fu","year":"2014","journal-title":"J Clin Invest"},{"key":"20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Lee","year":"2017","journal-title":"Lancet Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Hu","year":"2014","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Sharpe","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20112275","article-title":"Immunotherapy earns its spot in the ranks of cancer therapy","volume":"209","author":"Drake","year":"2012","journal-title":"J Exp Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"Suppl 3","key":"25","first-page":"39","article-title":"Prognostic and predictive markers for the new immunotherapies","volume":"28","author":"Atkins","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Averbuch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Nishino, Ramaiya, Hatabu, Hodi. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017.","DOI":"10.1038\/nrclinonc.2017.88"},{"key":"28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy","volume":"6","author":"Pantel","year":"2016","journal-title":"Cancer Discovery"},{"key":"29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12105-016-0765-y","article-title":"Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines","volume":"11","author":"Ma","year":"2017","journal-title":"Head Neck Pathol"},{"key":"30","first-page":"JCO2017733675","article-title":"Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study","author":"Hansen","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T23:13:19Z","timestamp":1660086799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":30,"journal-issue":{"issue":"68","published-print":{"date-parts":[[2017,12,22]]}},"alternative-id":["22938","29348907"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22938","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}